J.P. Morgan’s Cory Kasimov Shares Thoughts on ACADIA Pharmaceuticals (ACAD) Following FDA Approval of Nuplazid Formulations - Smarter Analyst

J.P. Morgan’s Cory Kasimov Shares Thoughts on ACADIA Pharmaceuticals (ACAD) Following FDA Approval of Nuplazid Formulations  Smarter AnalystJ.P. Morgan analyst Cory Kasimov is out with a research note on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD), after the drug maker announced FDA ...